Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Substituted 3β-Phenylethynyl Derivatives of 3α-Hydroxy-5α-pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of γ-Aminobutyric AcidA Receptors

Jon E. Hawkinson, Manuel Acosta-Burruel, Kevin C. Yang, Derk J. Hogenkamp, Jie-Sheng Chen, Nancy C. Lan, John A. Drewe, Edward R. Whittemore, Richard M. Woodward, Richard B. Carter and Ravindra B. Upasani
Journal of Pharmacology and Experimental Therapeutics October 1998, 287 (1) 198-207;
Jon E. Hawkinson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Acosta-Burruel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin C. Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derk J. Hogenkamp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jie-Sheng Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy C. Lan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Drewe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward R. Whittemore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard M. Woodward
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard B. Carter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravindra B. Upasani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Neuroactive steroids are positive allosteric modulators of γ-aminobutyric acidA (GABAA) receptor complexes. Synthetic modification generally does not increase neuroactive steroid potency beyond that of the naturally occurring progesterone metabolite, 3α-hydroxy-5α-pregnan-20-one (3α,5α-P). Recently, it has been shown that introduction of appropriately para-substituted phenylethynyl groups at the 3β-position of 5β steroids increases receptor potency. The present report presents the synthesis and pharmacological profile of an analogous series of 5α steroids. The most striking feature of this series is the further enhancement of in vitro andin vivo potency obtained. In particular, 3β-(p-acetylphenylethynyl)-3α-hydroxy-5α-pregnan-20-one (Co 152791) was 11-, 16- and 49-fold more potent than 3α,5α-P in modulating the binding of [35S]TBPS, [3H]flunitrazepam and [3H]muscimol, respectively, in rat brain membranes (Co 152791 IC50 or EC50 = 2–7.5 nM). Similarly, Co 152791 was 3- to 20-fold more potent than 3α,5α-P as an inhibitor of [35S]TBPS binding in human recombinant receptor combinations containing α1, α2, α3 or α5 and β2γ2L subunits (Co 152791 IC501.4–5.7 nM). Co 152791 displayed low efficacy and 3α,5α-P had low potency at α4/6β3γ2L GABAA receptor complexes. Interestingly, Co 152791 demonstrated remarkable potency as a potentiator of GABA-evoked currents in Xenopus oocytes expressing α1β2γ2L receptors (EC50 0.87 nM), being 184-fold more potent than 3α,5α-P. High in vitropotency was also reflected in enhanced in vivo activity in that Co 152791 exhibited exceptional anticonvulsant potency, protecting mice from pentylenetetrazol-induced seizures at a ∼5-fold lower dose than 3α,5α-P after i.p. administration (Co 152791 ED50 0.6 mg/kg). Moreover, Co 152791 was orally active (ED50 1.1 mg/kg) and exhibited a therapeutic index of 7 relative to rotorod impairment. The remarkable potency of Co 152791 as a positive allosteric modulator of GABAA receptors may be explained by its interaction with an auxiliary binding pocket in the neuroactive steroid binding site. In addition, modification at the 3β-position probably hinders metabolism of the 3α-hydroxy group contributing to the exceptional anticonvulsant potency of this compound relative to other neuroactive steroids.

Footnotes

  • Send reprint requests to: Dr. Ravindra B, Upasani, CoCensys, Inc., 201 Technology Dr., Irvine, CA 92618.

  • Abbreviations:
    Co 152791
    3β-(p-acetylphenylethynyl)-3α-hydroxy-5α-pregnan-20-one
    DMSO
    dimethylsulfoxide
    Emax
    maximal extent of enhancement or potentiation
    FR
    fractional response
    GABA
    γ-aminobutyric acid
    GABAmax
    the maximal current in response to GABA
    HEK
    human embryonic kidney
    Imax
    maximal extent of inhibition
    3α
    5α-P, 3α-hydroxy-5α-pregnan-20-one
    LRR
    loss-of-righting reflex
    PCR
    polymerase chain reaction
    PTZ
    pentylenetetrazol
    SAR
    structure-activity relationship
    [35S]TBPS
    [35S]t-butylbicyclophosphorothionate
    TI
    therapeutic index
    5αTHDOC
    3α,21-dihydroxy-5α-pregnan-20-one
    5βTHDOC
    3α,21-dihydroxy-5β-pregnan-20-one
    • Received December 11, 1997.
    • Accepted May 22, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 287, Issue 1
1 Oct 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Substituted 3β-Phenylethynyl Derivatives of 3α-Hydroxy-5α-pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of γ-Aminobutyric AcidA Receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Substituted 3β-Phenylethynyl Derivatives of 3α-Hydroxy-5α-pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of γ-Aminobutyric AcidA Receptors

Jon E. Hawkinson, Manuel Acosta-Burruel, Kevin C. Yang, Derk J. Hogenkamp, Jie-Sheng Chen, Nancy C. Lan, John A. Drewe, Edward R. Whittemore, Richard M. Woodward, Richard B. Carter and Ravindra B. Upasani
Journal of Pharmacology and Experimental Therapeutics October 1, 1998, 287 (1) 198-207;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Substituted 3β-Phenylethynyl Derivatives of 3α-Hydroxy-5α-pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of γ-Aminobutyric AcidA Receptors

Jon E. Hawkinson, Manuel Acosta-Burruel, Kevin C. Yang, Derk J. Hogenkamp, Jie-Sheng Chen, Nancy C. Lan, John A. Drewe, Edward R. Whittemore, Richard M. Woodward, Richard B. Carter and Ravindra B. Upasani
Journal of Pharmacology and Experimental Therapeutics October 1, 1998, 287 (1) 198-207;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Tissue Selectivity of Antidiabetic Agent Nateglinide: Study on Cardiovascular and β-Cell KATP Channels
  • Distribution in Rat Brain of Binding Sites of Kaliotoxin, a Blocker of Kv1.1 and Kv1.3 α-Subunits
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics